VEGF News and Research RSS Feed - VEGF News and Research

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.
IU researchers create virtual tissue model of diabetic retinopathy

IU researchers create virtual tissue model of diabetic retinopathy

By combining data on optometry patient's eyes with advanced computational methods, Indiana University researchers have created a virtual tissue model of diabetes in the eye. [More]
Losing weight can lower levels of some proteins linked to tumor growth

Losing weight can lower levels of some proteins linked to tumor growth

Overweight and obese women who lost weight through diet and exercise lowered the levels of certain proteins in their blood that play a role in angiogenesis, the process of blood vessel growth that can promote the growth and survival of cancer cells [More]
Phase III clinical study of promising prostate cancer drug reveals surprising results

Phase III clinical study of promising prostate cancer drug reveals surprising results

A recently published international clinical Phase III trial of a promising drug for treating advanced prostate cancer ended with surprising results: the new therapeutic agent failed to achieve any significant improvement in the overall survival of patients compared with the established standard treatment. [More]
Researchers find link between specific genetic pathway and development of mouth ulcers in lupus patients

Researchers find link between specific genetic pathway and development of mouth ulcers in lupus patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed for the first time an association between a specific genetic pathway and the development of mouth ulcers in patients with Systemic Lupus Erythematosus (SLE). [More]
Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Data presented today at the American Society of Clinical Oncology congress showed that cabozantinib, a next generation tyrosine kinase inhibitor (TKI) can extend the lives of patients by nearly two years following failure of one or more anti-angiogenic therapies almost five months longer than everolimus, a current standard of care therapy. [More]
Multiple cell and gene therapies can enhance cardiac function in mice modeled with MI

Multiple cell and gene therapies can enhance cardiac function in mice modeled with MI

Researchers at the University of Utah compared the therapeutic potential of umbilical cord-derived sub-epithelial cells (UC-SECs), bone marrow-derived mesenchymal stem cells (BM-MSCs) and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) -- all derived from human tissue -- along with genes (S100a1 and SDF-1a) and growth factor (VEGF165) to evaluate how injected biologics might enhance cardiac function in mice modeled with myocardial infarction (MI; commonly referred to as heart attack). [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability. [More]
Scientists find way to reduce need for secondary cataract surgery

Scientists find way to reduce need for secondary cataract surgery

Scientists at the University of East Anglia may have found a way to prevent complications from surgery to treat cataract - the world's leading cause of blindness. [More]
New study explores mechanisms that control size, shape of tubular organ systems

New study explores mechanisms that control size, shape of tubular organ systems

A new study from the group of Holger Gerhardt in collaboration with Katie Bentley's Lab addresses a long standing question in the wider field of developmental biology and tissue patterning in general, and in the vascular biology field in particular: 'What are the fundamental mechanisms controlling size and shape of tubular organ systems'. [More]
Scientists reveal mechanism involved in regulation of lymphangiogenesis

Scientists reveal mechanism involved in regulation of lymphangiogenesis

After an injury to tissues, such as in organ transplantation, the body grows new lymphatic vessels in a process known as lymphangiogenesis. A new study in Nature Communications reveals a mechanism involved in the regulation of this process, specifically in corneal transplants and infectious eye disease. [More]
Inserm study reveals potential of secondary system to improve heart function

Inserm study reveals potential of secondary system to improve heart function

Heart failure affects over one million people in France. Although the blood system is the first to have been explored for the purpose of improving heart function, a study by Inserm has revealed the potential of a secondary system that had previously received scant attention. [More]
Increased expression of VEGF-A promotes three common aging-related eye conditions

Increased expression of VEGF-A promotes three common aging-related eye conditions

A Massachusetts General Hospital investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of age-related macular degeneration (AMD) and also cataracts - in an animal model. [More]
Study identifies genetic differences in kidney tumors of African-Americans

Study identifies genetic differences in kidney tumors of African-Americans

A University of North Carolina Lineberger Comprehensive Cancer Center-led study has identified genetic differences in tumors of African-Americans with the most common type of kidney cancer compared with whites. [More]
Anticancer drug restores hearing in neurofibromatosis patients

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing. [More]
Drugs to help energy-starved photoreceptors offers new avenue for treating AMD , MacTel

Drugs to help energy-starved photoreceptors offers new avenue for treating AMD , MacTel

New research from Boston Children's Hospital could potentially change how doctors approach two blinding diseases: 'Wet' age-related macular degeneration (AMD), the leading cause of blindness in the elderly, and macular telangiectasia (MacTel). [More]
NK cells produce VEGF-A that promotes tumor growth

NK cells produce VEGF-A that promotes tumor growth

The immune system protects the body against cancer cells. The Elimination of cancer cells is an important task of NK cells. For NK cells to function properly, they require the activator STAT5. [More]
MGH study reveals effects of obesity on pancreatic and breast cancer

MGH study reveals effects of obesity on pancreatic and breast cancer

Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression. [More]
CHLA researchers develop novel model for studying neonatal lung disorder

CHLA researchers develop novel model for studying neonatal lung disorder

Investigators at The Saban Research Institute of Children's Hospital Los Angeles have created a novel model for studying a lung disorder of newborn babies. Their study, published in PLOS ONE on February 10, describes the first model that allows investigators to consider the chronic effects of developmental lung disease. [More]
Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Stopping the growth of blood vessels in tumours is a key target for glioblastoma therapies, and imaging methods are essential for initial diagnosis and monitoring the effects of treatments. While mapping vessels in tumours has proven a challenge, researchers have now developed a combined magnetic resonance imaging (MRI) and ultramicroscopy 'toolkit' to study vessel growth in glioma models in more detail than previously possible. [More]
Advertisement
Advertisement